Viridian

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Well, Pivotal, Therapy, TED, Graves' ophthalmopathy, PD, ADAS, Serum, Data, Patient, Clinical study design, Cavg, Cmin, Pharmacology, Half-life, Trial of the century, Stiffness, Growth, Pharmaceutical industry, Vaccine, Copper, Viridian

“The data reinforce our confidence in VRDN-003’s rapid development as a low-volume, self-administered, subcutaneous product.

Key Points: 
  • “The data reinforce our confidence in VRDN-003’s rapid development as a low-volume, self-administered, subcutaneous product.
  • VRDN-003 is designed to maintain the clinical response of VRDN-001 IV while significantly increasing patient convenience.
  • Dosing Flexibility for Pivotal Development: VRDN-003 modeling demonstrates dosing flexibility for the program’s anticipated global pivotal development.
  • Based on these positive results and the expected development timeline for VRDN-003, both VRDN-001 SC and VRDN-002 SC development have been deprioritized.

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 21, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Webcast, Conference, Therapy, Pharmaceutical industry, Broadcasting, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, November 30 at 11:15am ET in Miami, Florida.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Thursday, November 30 at 11:15am ET in Miami, Florida.
  • A live webcast of the presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com .
  • A replay of the webcast will be available following the completion of the event.

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Other Science, Science, Safety, D, Pharmaceutical industry in Switzerland, Therapy, TED, IND, Investment, Patient, Neonatal Fc receptor, LDL, Conditional sentence, Pharmacokinetics, Half-life, Immunoglobulin G, Intravenous therapy, Pharmaceutical industry, Management, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the third quarter ended September 30, 2023.
  • The ongoing THRIVE Phase 3 clinical trial of VRDN-001 in patients with active TED continues to enroll patients with topline results expected in mid-2024.
  • Net Loss: The company’s net loss was $47.7 million for the third quarter of 2023, compared with $28.9 million for the same period last year.
  • Viridian will not be hosting a conference call to discuss its third quarter financial results.

Global Graves' Disease Drug Pipeline Research Report 2023: Comprehensive Insights About 8+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Health, Pharmaceutical, CAS, Neonatal Fc receptor, Therapy, Grave, II, Exophthalmos, Linsitinib, Graves' ophthalmopathy, News, Discovery, Graves' disease, Viridian, Disease, Clinical trial, TED, Mergers and acquisitions, Diplopia, Immunoglobulin G, Recycling, NDA, Autoimmunity, Patient, Pharmaceutical industry, Vaccine, Phase

The "Graves' Disease - Pipeline Insight, 2023" report offers comprehensive insights into the Graves' Disease pipeline landscape, encompassing information on more than 8 companies and over 10 pipeline drugs.

Key Points: 
  • The "Graves' Disease - Pipeline Insight, 2023" report offers comprehensive insights into the Graves' Disease pipeline landscape, encompassing information on more than 8 companies and over 10 pipeline drugs.
  • The report delivers a thorough understanding of the current scenario and growth prospects within the Graves' Disease indication.
  • It furnishes an extensive overview of the Graves' Disease pipeline landscape, including information on the disease itself and treatment guidelines.
  • The assessment section of the report includes a comprehensive commercial assessment of Graves' Disease, as well as a clinical evaluation of the pipeline products currently in development.

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Pharmaceutical, Health, Conference, Therapy, Webcast, Pharmaceutical industry, Broadcasting, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 4:00 p.m. GMT in London, UK.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 4:00 p.m. GMT in London, UK.
  • A live webcast of the presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com .
  • A replay of the webcast will be available following the completion of the event.

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Pharmaceutical, Health, Pharmacokinetics, Graves' ophthalmopathy, AAO, Trial of the century, Safety, Therapy, American Academy, Patient, TED, Abstract, Pharmaceutical industry, Viridian

In an oral presentation, encore data for intravenous VRDN-001 including preliminary clinical results from a Phase 1/2 study will be highlighted.

Key Points: 
  • In an oral presentation, encore data for intravenous VRDN-001 including preliminary clinical results from a Phase 1/2 study will be highlighted.
  • Viridian will also present encore preclinical data for VRDN-003, which is a half-life extended antibody targeting IGF-1R that is designed to be a potentially best-in-class, self-administered, infrequent, and low-volume injection for patients.
  • Subcutaneous VRDN-003 is currently in a Phase 1 clinical study in healthy volunteers to evaluate its pharmacokinetics and safety.
  • Viridian is on track to select its lead subcutaneous IGF-1R program by year end 2023 and expects VRDN-001 THRIVE Phase 3 topline results in active TED in mid-2024, both as previously disclosed.

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

Retrieved on: 
Monday, October 30, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Citadel, LP, Sale, Security (finance), IND, Rare, Paradigm, Investment, Genzyme, LDL, Clinical trial, TED, Immunoglobulin G, Stifel, Autoimmunity, Safety, Therapy, Exchange, Patient, RTW, Colorado College, Pharmaceutical industry, Management, Neonatal Fc receptor, Boston College, Viridian

Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases.

Key Points: 
  • Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases.
  • He most recently served as President, Chief Financial and Operating Officer of Magenta Therapeutics.
  • Proceeds will be used to fund pipeline programs, including the FcRn portfolio, and for general corporate purposes and working capital.
  • Jefferies, Evercore ISI, and Stifel are acting as lead placement agents for the private placement financing.

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

Retrieved on: 
Thursday, October 26, 2023
Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Graves' ophthalmopathy, Therapy, Patient, Pharmaceutical industry in Switzerland, TED, Pharmaceutical industry, Viridian

As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED).

Key Points: 
  • As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidates for the treatment of thyroid eye disease (TED).
  • “Developing a subcutaneous therapy is an essential part of our vision to offer the most comprehensive set of therapeutic options to the TED community.
  • “Thus, it’s critical that we continue to improve our therapy by packaging it in a delivery device that is as convenient and user-friendly as possible.
  • We engaged in a rigorous selection process and concluded that, based on its strong track record of drug-device combination approvals in multiple disease areas, Ypsomed is the ideal partner to supply such a device.

Unrivaled Brands Ranked Among Most Improved “Credit Quality” of Cannabis Peers

Retrieved on: 
Tuesday, October 24, 2023
Week, Unrivaled, Canyon Capital Advisors, Total, Acquisition, Tax, Health, OTCQB, Capital, Audit, Viridian

SANTA ANA, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Unrivaled Brands, Inc. (OTCQB: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a cannabis company with operations throughout California, is pleased to announce that on October 13, 2023, Viridian Capital Advisors (“Viridian”) released their Capital Chart of the Week, designed to highlight significant investment, valuation, and M&A trends within the cannabis sector, ranking Unrivaled as having one of the most improved measures of credit quality relative to its publicly traded cannabis peers.

Key Points: 
  • SANTA ANA, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Unrivaled Brands, Inc. (OTCQB: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a cannabis company with operations throughout California, is pleased to announce that on October 13, 2023, Viridian Capital Advisors (“Viridian”) released their Capital Chart of the Week, designed to highlight significant investment, valuation, and M&A trends within the cannabis sector, ranking Unrivaled as having one of the most improved measures of credit quality relative to its publicly traded cannabis peers.
  • Its calculations were indicated as having been current as of October 13, 2023.
  • Chris Rivera, Unrivaled’s Interim Chief Financial Officer, said, “As part of the Unrivaled turnaround, we have been and continue to be focused on building a foundation on which Unrivaled can continue to grow.
  • The recognition of the Company’s continued improvement is further testament to our work and reflects a reduction of over $53.0 million in debt.

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Monday, September 25, 2023
Health, General Health, Research, Science, Optical, Biotechnology, University of Antwerp, Thalassemia, University, Doctor of Philosophy, HIV, Free University of Brussels (1834–1969), Medicine, Biogen, Beth Israel Deaconess Medical Center, CMO, Teaching hospital, Harvard Medical School, Graves' ophthalmopathy, VUB, Patient, Progressive multifocal leukoencephalopathy, Sickle cell disease, R, Therapy, Free University, Safety, TED, Pharmaceutical industry, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.
  • During her time at Agios, she has overseen early- and late-stage clinical development globally across multiple indications, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
  • “I’ve dedicated much of my career to developing medicines for underserved patient populations across a range of therapeutic areas.
  • She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.